Allergan PLC. (NYSE:AGN)‘s stock had its “hold” rating reaffirmed by investment analysts at Edward Jones in a report issued on Wednesday, October 18th.
Several other equities analysts also recently commented on AGN. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $285.00 target price on shares of Allergan PLC. in a research report on Wednesday, September 6th. Credit Suisse Group set a $243.00 target price on Allergan PLC. and gave the company an “outperform” rating in a research report on Tuesday, October 17th. BidaskClub downgraded Allergan PLC. from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Wells Fargo & Company reaffirmed a “buy” rating on shares of Allergan PLC. in a research report on Monday, October 2nd. Finally, Deutsche Bank AG reissued a “buy” rating and set a $273.00 price target (up previously from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $252.39.
Allergan PLC. (NYSE AGN) traded up 1.41% during mid-day trading on Wednesday, reaching $178.82. The company’s stock had a trading volume of 3,836,922 shares. Allergan PLC. has a 52-week low of $174.66 and a 52-week high of $256.80. The company has a 50 day moving average of $205.52 and a 200-day moving average of $228.30. The stock has a market cap of $59.78 billion, a PE ratio of 5.45 and a beta of 1.15.
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business’s revenue was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.35 earnings per share. Equities analysts forecast that Allergan PLC. will post $16.21 earnings per share for the current year.
Allergan PLC. declared that its Board of Directors has initiated a stock buyback program on Monday, September 25th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to repurchase up to 2.8% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.
ILLEGAL ACTIVITY WARNING: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/10/28/allergan-plc-agn-given-hold-rating-at-edward-jones.html.
A number of large investors have recently made changes to their positions in AGN. Waldron LP bought a new position in Allergan PLC. during the 1st quarter worth $348,000. Mirae Asset Global Investments Co. Ltd. raised its position in Allergan PLC. by 246.8% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 113,582 shares of the company’s stock worth $27,137,000 after purchasing an additional 80,829 shares during the last quarter. Neville Rodie & Shaw Inc. raised its position in Allergan PLC. by 11.0% during the 1st quarter. Neville Rodie & Shaw Inc. now owns 3,074 shares of the company’s stock worth $734,000 after purchasing an additional 305 shares during the last quarter. Airain ltd bought a new position in Allergan PLC. during the 1st quarter worth $241,000. Finally, Ingalls & Snyder LLC raised its position in Allergan PLC. by 20.6% during the 1st quarter. Ingalls & Snyder LLC now owns 1,254 shares of the company’s stock worth $300,000 after purchasing an additional 214 shares during the last quarter. 82.04% of the stock is owned by institutional investors and hedge funds.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.